U.S. Central Nervous System Therapeutic Market Size & Outlook
- Pharmaceuticals
- Neurology Drugs
- Central Nervous System Therapeutic Market Outlook
- Neurology Drugs
Global Market
Related Markets
Ask a question about the central nervous system therapeutic market
U.S. central nervous system therapeutic market highlights
- The U.S. central nervous system therapeutic market generated a revenue of USD 51,462.0 million in 2025 and is expected to reach USD 98,647.3 million by 2033.
- The U.S. market is expected to grow at a CAGR of 8.7% from 2026 to 2033.
- In terms of segment, neurodegenerative diseases was the largest revenue generating disease in 2025.
- Neurodegenerative Diseases is the most lucrative disease segment registering the fastest growth during the forecast period.
Central nervous system therapeutic market data book summary
| Market revenue in 2025 | USD 51,462.0 million |
| Market revenue in 2033 | USD 98,647.3 million |
| Growth rate | 8.7% (CAGR from 2026 to 2033) |
| Largest segment | Neurodegenerative diseases |
| Fastest growing segment | Neurodegenerative Diseases |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
| Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.1% of the global central nervous system therapeutic market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. central nervous system therapeutic market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 3,449.1 million by 2033.
initiatives being undertaken by regulatory bodies to support the pharmaceutical companies in developing novel therapies is expected to drive the market on American Brain Foundation, the prevalence of CNS disorders. The U.S. FDA has designated CNS pharmaceutical berubicin as an orphan drug for treatment of malignant gliomas.
No credit card required*
Publish Date: Jan 12, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Central Nervous System Therapeutic Market Scope
Central Nervous System Therapeutic Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Otsuka Pharmaceutical | View profile | 251-500 | Tokyo, Tokyo, Japan, Asia | www.otsuka.co.jp/en/ |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Biogen Inc | View profile | 7,570 | 225 Binney Street, Cambridge, MA, United States, 02142 | www.biogen.com |
U.S. Central Nervous System Therapeutic Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Central Nervous System Therapeutic Market Outlook will help companies and investors design strategic landscapes.
Neurodegenerative Diseases was the largest segment with a revenue share of 36.91% in 2025.
Horizon Databook has segmented the U.S. central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2021 to 2033.
initiatives being undertaken by regulatory bodies to support the pharmaceutical companies in developing novel therapies is expected to drive the market on American Brain Foundation, the prevalence of CNS disorders. The U.S. FDA has designated CNS pharmaceutical berubicin as an orphan drug for treatment of malignant gliomas.
- U.S. Central Nervous System Therapeutic Market Disease Outlook (Revenue, USD Million , 2021-2033)
- Neurovascular Diseases
- CNS Trauma
- Mental Health
- Neurodegenerative Diseases
- Infectious Diseases
- CNS Cancer
- Others
- U.S. Central Nervous System Therapeutic Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Antidepressants
- Antipsychotics
- Antiepileptics (AEDs)
- Dopaminergic Agents
- Neuroprotective Agents
- Immunomodulators
- Others
- U.S. Central Nervous System Therapeutic Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Others
Reasons to subscribe to Central Nervous System Therapeutic Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Central Nervous System Therapeutic Market Outlook databook
- Our clientele includes a mix of Central Nervous System Therapeutic Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Central Nervous System Therapeutic Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Central Nervous System Therapeutic Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Central Nervous System Therapeutic Market, 2021-2033 (US$M)
U.S. central nervous system therapeutic market statistics, by disease, 2021-2033 (US$M)
